Clinical trial approval / initiation

Explore the landscape of Clinical trial approval / initiation in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial approval / initiation to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Suzhou Rigerna Therapeutics' RG002C0106 Injection Supplemental Application Accepted by China's CDE – Class 1 Chemical Drug Enters Regulatory Review
CompanyDrug

Suzhou Rigerna Therapeutics’ RG002C0106 Injection Supplemental Application Accepted by China’s CDE – Class 1 Chemical Drug Enters Regulatory Review

Data from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) show that a supplemental application for RG002C0106 Injection, submitted by Suzhou Rigerna Therapeutics Co., Ltd.…

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

S-Evans Biosciences Receives NMPA Tacit Approval for Stem Cell Therapy in ARDS

CompanyDrug

Hopstem Biotechnology’s hNPC01 Receives Tacit Approval for Stroke Sequelae Treatment from CDE

CompanyDrug

BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447

CompanyDrug

Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China

CompanyDrug

Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial

CompanyDrug

TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody

CompanyDrug

IASO Bio Receives FDA IND Approval for IASO-782 for Autoimmune Disorders

CompanyDrug

MicuRx Pharmaceuticals’ MRX-4/Contezolid Combo Receives Clinical Trial Approvals for Diabetic Foot Infection

Show More